Shanghai Hengrui Pharmaceutical Co., Ltd.

Jiangsu Hengrui Medicine Company Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Changzhou Hansoh Pharmaceutical Co., Ltd.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Shanghai Hansoh Biomedical Co., Ltd.

Suzhou Suncediabiopharmaeuticals Co., Ltd.

Hansoh (shanghai) Healthtech Co., Ltd.

Jinagsu Hengrui Medicine Co., Ltd

Weikang Tao

Feng He

Lianshan Zhang

Qiyue Hu

Piaoyang Sun

Fanglong Yang

Xin Ye

Xiangdong Qu

Hua Ying

Hu Ge

Dongbing Cui

Lei Zhang

Ling L Zhang

Yayuan Fu

Guoqing Cao

Jinping Shi

Yifang Wang

Zhuoxiao Cao

Jinming Gu

Ling Zhang

Fei Li

Ting Ting Zhang

Jijun Yuan

Jingjing Yan

Liangliang Zheng

Shaoyu Xu

Linghang Zhuang

Wei He

Yang Chen

Li Yang

Dong Liu

Guobao Zhang

Gang Chen

Rumin Zhang

Xiaodong Li

Liuqing Yang

Xing Fan

Mingxun He

Tingting Li

Xiaohua Wang

Xiao Wu

Jiajian Liu

Biao Lu

Jianyan Xu

Weimin Wang

Suxing Liu

Xiaoling Gu

Guimei Yang

Jufang Lin

Houcong Jin

Zhibin Xu

Hong Li

Bin Wang

Jie Li

Jian Liu

Minsheng Zhang

Ying Zhang

Tao Liu

Zhen Zhang

Heping Wu

Fengqi Zhang

Yinfa Yan

Xiaomin Zhang

Yali Wang

Zhen Yan

Jiahua Jiang

Yan Fang

Guangyuan Shen

Yiqian Chen

Shanghai Yu

Ting Zhang

Pingping Wang

Guiyang Jiang

Xiaodong Shen

Xiqian Zhang

Fangfang Jin

Jindong Liang

Shenglan Wang

Xiao Luo

Chunfei Wang

Zhigao Zhang

Dong Ma

Junzhuan Qiu

Ziyong Sun

Jiping Zha

Jingping Wei

Haoying Zhang

Binqiang Feng

Kan Chen

Chunfeng Shu

Dianqiang Ma

Puhui Li

Xinzhu Zhang

Huiqing Yuan

Chunying Song

Matthew Miller

Yuna Yan

Junzhen Zhang

Lei Chen

Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.

Fused imidazole derivative, preparation method therefor, and medical use thereof

The present disclosure relates to an anti-Claudin 18.2 antibody and an application thereof. Specifically, the present invention relates to an anti-Claudin 18.2 antibody; a mouse-derived antibody, chimeric antibody, humanized antibody and antigen-binding fragment thereof which contain a CDR of the anti-Claudin 18.2 antibody, and a use thereof as a medicine. In particular, the present disclosure relates to a use of the anti-Claudin 18.2 antibody in the preparation of a drug for treating Claudin 18.2 positive diseases or disorders.

Anti-Claudin 18.2 antibody and application thereof

Provided are an anti-PD-1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. Specifically, provided are a humanized anti-PD-1 antibody containing a specific CDR region and an antigen-binding fragment thereof, a pharmaceutical composition containing the anti-PD-1 antibody and the antigen-binding fragment thereof, and a used thereof as medicament. In particular, provided is a use of the humanized anti-PD-1 antibody in the preparation of the medicament for treating PD-1 associated diseases or disorders.

Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof

The present disclosure relates to a tricyclic tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, the present disclosure relates to a tricyclic tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a pharmaceutical composition comprising said derivative, a use thereof as an estrogen receptor modulator, and a use thereof in preparing a drug for treating estrogen receptor-mediated or dependent diseases or disorders. The substituents in general formula (I) are the same as those defined in the description.

Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

Antibody capable of binding to thymic stromal lymphopoietin and use thereof

Disclosed by the present invention are an anti-B7H3 antibody-exatecan analog conjugate, a preparation method therefor and an anti-tumor medicinal use thereof.

Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof

Murine, chimeric or humanized anti-Abeta antibody having a specific CDR region, an antigen-binding fragment thereof, a pharmaceutical composition thereof, and usage thereof. Use of a humanized anti-Abeta antibody for the preparation of drugs for the treatment of a disease or disorder (such as Alzheimer's disease) caused by amyloid beta protein.

Anti-Aβ antibodies and antigen-binding fragments thereof

An indazole derivative, a preparation method therefor, and a pharmaceutical application thereof. In particular, the present invention relates to an indazole derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and a use of the derivative as an estrogen receptor modulator in the prevention and/or treatment of an estrogen receptor mediated or dependent disease or condition, the disease being particularly preferably breast cancer. The definition of each substituent in the general formula (I) is the same as that in the description.

Indazole derivative, preparation method therefor, and pharmaceutical application thereof

The present disclosure relates to a CD3 antibody and a pharmaceutical use thereof. Specifically, the present disclosure relates to forming a multi-specificity antibody by using CD3 antibody and binding molecules of another target. The multi-specificity antibody may simultaneously bind to CD3 and another tumor-associated antigen, and bind and activate CD3-positive T cells while binding tumor-associated antigen-expressing cells, thereby promoting T cells specifically killing tumor cells that express tumor-associated antigens. In addition, the present disclosure also provides a preparation and application of a multi-specific antibody.

CD3 antibody and pharmaceutical use thereof

Provided are an IL-5 antibody, an antigen binding fragment thereof, and a medical application therefor. The present invention comprises a mouse-derived antibody containing an IL-5 antibody CDR region, a chimeric antibody, a humanized antibody, and a pharmaceutical composition comprising said IL-5 antibody and said antigen binding fragment thereof, as well as the use of the pharmaceutical composition as a drug.

IL-5 antibody, antigen binding fragment thereof, and medical application therefor

Disclosed are a pyridopyrimidine derivative as shown in general formula (I), a preparation method therefor and a pharmaceutical composition containing the derivative, and the use thereof as a therapeutic agent, particularly as a TLR8 agonist, wherein each substituent of general formula (I) is the same as those defined in the description.

Pyridopyrimidine derivative, preparation method therefor and medical use thereof

Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.

LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof

Growing community of inventors

Shanghai, China

Weikang Tao